Clinical Proteomic Research for the Brain ("CPR Brain")
The study of plasma and urine proteomic profiles in patients with ischemic brain injury is important to better understanding of the mechanisms by which thrombolytic agents or other therapy affects clinical outcomes. The purpose of this study is to study the proteomic profile of patients with ischemic brain injury and compare it to control subjects without ischemic brain injury, subjects with other chronic neurologic diseases or systemic vascular diseases, and pre- and post- therapy which may be associated with, or predictive of, therapeutic outcome.
The investigators hypothesize that there is a unique set of proteins expressed in serum and urine in patients with ischemic brain injury that may provide a more complete understanding of ischemic brain injury pathophysiology.
Ultimately, this study may provide information of direct relevance to the medical care of a large proportion of patients with ischemic brain injury and other neurologic diseases in the future. And proteomic proteomic profile may provide important information about the roles of specific biomarkers. Perhaps the prevention of ischemic injury related complications.
Ischemic Brain Injury
Patent Foramen Ovale (PFO)
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Clinical Proteomic Research on the Brain|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00983723
|Contact: MingMing Ning, M.D. (PI)||617-726-8459||CPRBrain@mgh.harvard.edu|
|United States, Massachusetts|
|Clinical Proteomics Research Center, Massachusetts General Hospital||Recruiting|
|Boston, Massachusetts, United States, 02114|
|Contact: Mingming Ning, MD MMsc 617-726-8459 CPRBrain@mgh.harvard.edu|
|Principal Investigator: MingMing Ning, M.D.|
|Sub-Investigator: Ferdinando Buonanno, M.D.|
|Sub-Investigator: Eng H Lo, PhD|
|Principal Investigator:||MingMing Ning, M.D.||Massachusetts General Hospital|